» Articles » PMID: 34471825

Irreversible Electroporation: Background, Theory, and Review of Recent Developments in Clinical Oncology

Overview
Journal Bioelectricity
Specialty Biology
Date 2021 Sep 2
PMID 34471825
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Irreversible electroporation (IRE) has established a clinical niche as an alternative to thermal ablation for the eradication of unresectable tumors, particularly those near critical vascular structures. IRE has been used in over 50 independent clinical trials and has shown clinical success when used as a standalone treatment and as a single component within combinatorial treatment paradigms. Recently, many studies evaluating IRE in larger patient cohorts and alongside other novel therapies have been reported. Here, we present the basic principles of reversible electroporation and IRE followed by a review of preclinical and clinical data with a focus on tumors in three organ systems in which IRE has shown great promise: the prostate, pancreas, and liver. Finally, we discuss alternative and future developments, which will likely further advance the use of IRE in the clinic.

Citing Articles

Pulsed field ablation in medicine: irreversible electroporation and electropermeabilization theory and applications.

Jacobs E, Rubinsky B, Davalos R Radiol Oncol. 2025; 59(1):1-22.

PMID: 40014783 PMC: 11867574. DOI: 10.2478/raon-2025-0011.


Interleaflet Translocation of Second-Harmonic-Generation-Active Dye Molecules in Phospholipid Bilayers with Transmembrane Pores.

Shigematsu T, Shinoda Y, Takagi R, Ujihara Y, Sugita S, Nakamura M Langmuir. 2025; 41(5):3209-3219.

PMID: 39875332 PMC: 11823627. DOI: 10.1021/acs.langmuir.4c03943.


A Flexible, Implantable, Bioelectronic Electroporation Device for Targeted Ablation of Seizure Foci in the Mouse Brain.

Matta R, Balogh-Lantos Z, Fekete Z, Baca M, Kaszas A, Moreau D Sensors (Basel). 2025; 25(1.

PMID: 39796794 PMC: 11722952. DOI: 10.3390/s25010004.


Modulating the Cell Death Immune Response for Electroporation Treatments.

David K, Alinezhadbalalami N, Salameh Z, Aycock K, Allen I, Davalos R Bioelectricity. 2024; 6(4):263-271.

PMID: 39712216 PMC: 11656017. DOI: 10.1089/bioe.2024.0019.


A multicenter, randomized, parallel-controlled clinical trial protocol to evaluate the safety and efficacy of irreversible electroporation compared with radiofrequency ablation for the treatment of small hepatocellular carcinoma.

Cheng C, Xu M, Pan J, Chen Q, Li K, Xu D World J Surg Oncol. 2024; 22(1):332.

PMID: 39707376 PMC: 11662571. DOI: 10.1186/s12957-024-03614-z.


References
1.
Martin 2nd R, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C . Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 2015; 262(3):486-94. DOI: 10.1097/SLA.0000000000001441. View

2.
DeBruin K, Krassowska W . Modeling electroporation in a single cell. I. Effects Of field strength and rest potential. Biophys J. 1999; 77(3):1213-24. PMC: 1300413. DOI: 10.1016/S0006-3495(99)76973-0. View

3.
Kinosita Jr K, Tsong T . Hemolysis of human erythrocytes by transient electric field. Proc Natl Acad Sci U S A. 1977; 74(5):1923-7. PMC: 431044. DOI: 10.1073/pnas.74.5.1923. View

4.
Guenther E, Klein N, Zapf S, Weil S, Schlosser C, Rubinsky B . Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments. PLoS One. 2019; 14(4):e0215093. PMC: 6464181. DOI: 10.1371/journal.pone.0215093. View

5.
Pandya G, Shelat V . Radiofrequency ablation of pancreatic ductal adenocarcinoma: The past, the present and the future. World J Gastrointest Oncol. 2015; 7(2):6-11. PMC: 4309949. DOI: 10.4251/wjgo.v7.i2.6. View